[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-ERNA":3,"homepage-market-summary":29,"stock-news-ERNA":171},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"ERNA","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Ernexa Therapeutics Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.","5","Cambridge, MA",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":16,"change":20,"percent_change":20,"volume":21,"transactions":22,"vwap":23,"high_52w":24,"low_52w":25,"avg_volume_52w":26,"range_52w_percent":27,"record_count":28},2.96,3,3.2798,2.9,0,40714.203757,673,3.0596,71.5,2.84,579649.909797004,0.2,8835,{"status":30,"indices":31,"watchlist":75,"sectors":97,"benchmarks":153},"success",[32,40,47,54,61,68],{"symbol":33,"name":34,"price":35,"change":36,"pct_change":37,"is_up":38,"sparkline":39,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":41,"name":42,"price":43,"change":44,"pct_change":45,"is_up":38,"sparkline":46,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":48,"name":49,"price":50,"change":51,"pct_change":52,"is_up":38,"sparkline":53,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":55,"name":56,"price":57,"change":58,"pct_change":59,"is_up":38,"sparkline":60,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":62,"name":63,"price":64,"change":65,"pct_change":66,"is_up":38,"sparkline":67,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":69,"name":70,"price":71,"change":72,"pct_change":73,"is_up":14,"sparkline":74,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[76,83,90],{"symbol":77,"name":78,"price":79,"change":80,"pct_change":81,"is_up":38,"sparkline":82,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":84,"name":85,"price":86,"change":87,"pct_change":88,"is_up":38,"sparkline":89,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":91,"name":92,"price":93,"change":94,"pct_change":95,"is_up":38,"sparkline":96,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[98,103,108,113,118,123,128,133,138,143,148],{"name":99,"etf":100,"change":101,"price":102,"is_up":38},"Technology","XLK",1.01,199.81,{"name":104,"etf":105,"change":106,"price":107,"is_up":38},"Financials","XLF",0.06,53.49,{"name":109,"etf":110,"change":111,"price":112,"is_up":14},"Healthcare","XLV",-0.01,166.18,{"name":114,"etf":115,"change":116,"price":117,"is_up":38},"Consumer Cycl","XLY",1.13,110.04,{"name":119,"etf":120,"change":121,"price":122,"is_up":38},"Consumer Staples","XLP",0.25,80.53,{"name":124,"etf":125,"change":126,"price":127,"is_up":38},"Energy","XLE",0.4,62.95,{"name":129,"etf":130,"change":131,"price":132,"is_up":38},"Industrials","XLI",0.78,169.95,{"name":134,"etf":135,"change":136,"price":137,"is_up":38},"Materials","XLB",0.66,48.86,{"name":139,"etf":140,"change":141,"price":142,"is_up":38},"Real Estate","XLRE",0.32,40.81,{"name":144,"etf":145,"change":146,"price":147,"is_up":38},"Utilities","XLU",0.38,39.83,{"name":149,"etf":150,"change":151,"price":152,"is_up":38},"Comm Services","XLC",0.35,110.32,[154,159,163,167],{"ticker":155,"name":156,"price":157,"change":158,"is_up":38},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":160,"name":161,"price":162,"change":88,"is_up":38},"QQQ","Invesco QQQ Trust",749.58,{"ticker":164,"name":165,"price":166,"change":52,"is_up":38},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":168,"name":169,"price":170,"change":66,"is_up":38},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":172,"articles":173},10,[174,180,186,192,197,203,209,214,220,226],{"title":175,"link":176,"pubDate":177,"description":178,"source":179},"An ovarian cancer model showed 100% survival with a treatment combination. Human testing is planned for early 2027. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAFBVV95cUxQOGV6UklPLUYtSngxMWJDdmJaS2RQNk53YlA4MW1XSVFyWnZJcXRsRkVVbTdIUDhGeWlBYkxHVVo2eTlxT0JkWm95Tkt1VUh1U3QwaVlVbmZadnY3WmZfV21tSm5VWUktaDlSV0Y3M19DZjl0T3JobE5SQnFLWjlCdEIzRGxMQ2xrRE9kSGlpTkRfVVZicVFVM0IxbjR4ZWR0cHFiZWVWWjVDSnpnQnotSFVPZEpLc1Q0LUdnWTk2amE?oc=5","Thu, 01 Oct 2026 13:20:00 GMT","An ovarian cancer model showed 100% survival with a treatment combination. Human testing is planned for early 2027. stocktitan.net","stocktitan.net",{"title":181,"link":182,"pubDate":183,"description":184,"source":185},"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - markets.businessinsider.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiqAJBVV95cUxQZm8yd2FWeWY1Sno0MXZoSmpxU3BWVVRNSTMxbjBjOGJfaHRZRVhpb3dSbXk4aU9LTzI1T1FKRmlsbUd3V2RGZk9UODUtRmRoNE04UWZDYml4WnRXNWJIQ1hYMjJseTVIMnVNWlZXd1lJOXNXNFVrZHV2SVRPbFhwb2pCU1VxUEx1SnJ3ZE0yVDdqVWxkTzE3eUtiSFlSWEFoc01CdF93MXRKREVVVkJWT1BtRXJheVl1bU0zOWctNkxjcUxfX01OLXg1dlpnejc2SVNnbHFaRTRjcVhUaXZmZlRlSE1fTDQ3ZzBFaDIyZEk5Y2M0bkZMVVBKUXcxQkF2dHZXbVJLV200SEpJVkRYMk1HWkNUVmFheWFfWDFwY1Z0cEYwckdicQ?oc=5","Wed, 30 Sep 2026 12:49:39 GMT","Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND markets.businessinsider.com","markets.businessinsider.com",{"title":187,"link":188,"pubDate":189,"description":190,"source":191},"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivAFBVV95cUxPdHhmSTJJRWhJUnpObTJZbjZ0d1B3YUswbWZlUEtSb3VuRjhPenJ4MTE2WGlPV3g3cVlUaFh3NXNIOFp4b2NDSlRWYndoOWlxcGpPWm5ySGE0LTJ5NmNsM21GeUUyZkhjR2xjaTBuMXZtTG82RVhmaW1fZWR2bmpjY2RBSXEtZjVoZXpqY0ItYmVMeV9Rdk81MnJlUFZQcWRySlhJbjdkUElxbFItaE1uTHR3NTlBS3REMXdibg?oc=5","Wed, 30 Sep 2026 12:05:54 GMT","12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga","Benzinga",{"title":193,"link":194,"pubDate":195,"description":196,"source":179},"Ernexa (ERNA) director logs zero insider stake in new ownership report - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiywFBVV95cUxPRDkwOHd0NC1FckYzS0RhZDBiUTlwbUlNQUNGalJVTmVTOXlMdUZjVi1wS0E1djJuSklLM042OFluRUhLbnVKQlI2M2laNzZMYU9lbWxNczMyV0tBc1pVVkpWQnpXaEdST3NXX3pJOVdOOWJnRjZQXzQ3WWFGLVdmdmlHR3FFU05KU1RJNTRacC1mNV9wcmtnSmNvN2Y2c1BjWThZNkJ6ZlZKOXV4T1ZYMWpUOFI1TVJvYThDRm5FcDFnWktqRmNJX3Y0aw?oc=5","Tue, 22 Sep 2026 20:13:44 GMT","Ernexa (ERNA) director logs zero insider stake in new ownership report stocktitan.net",{"title":198,"link":199,"pubDate":200,"description":201,"source":202},"Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com - Investing.com South Africa","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxQYlNDNHdvOUxEVVNGZFV4N0tLYkNaUV9iaXFmWTh1NWpka3g1YXoxOEY5aHpjdVR0a3NydUN2akZUSXJ1MlpaUG90R2ZZR2F1Sl9GTldadEI2MU9VWFZrUEEzckNGclJZTFBRZUh4YnZpcjVhaGZuNV9lTmYweS1mRjhkSEFhbmFMTWU0ZHJHeDhsc0dUSU41ZjZXRkx4b05YSEY0Um10R0RObE0yT3dtaXNfenQwME1yR0t3?oc=5","Wed, 30 Sep 2026 12:54:08 GMT","Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com Investing.com South Africa","Investing.com South Africa",{"title":204,"link":205,"pubDate":206,"description":207,"source":208},"CORZ Stock Soars To Record High On Oklahoma Data Center Plan Reaching Gigawatt Scale - Stocktwits","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi2gFBVV95cUxPVWRkZnI3MU4tLTdoZER5RldVNzJPU1ZQNEhwV2FYbEYzNENjNDdVSTAtcjdGRTh3Nl9JX3o3RU5tdmFxTXg4YUJ5dGc1VkNVVFdFOUwwYmNkWUJsdnQwZGY2OHJXSXdlZnlqd1EyY1MwTmlFYzU1ZlJsTWNNTVRYOG5WWU5MSXdnYnV2RmNwdGNXT3I3NWhSejlObHFHd1JFQUxFaWNoVXZwRUc5Tm9wSXdITElCeVRkXzd4elJ1elRjOE5Ick11TVJNc20zYkxTamlCSWZMdmFjdw?oc=5","Sat, 03 Oct 2026 20:47:35 GMT","CORZ Stock Soars To Record High On Oklahoma Data Center Plan Reaching Gigawatt Scale Stocktwits","Stocktwits",{"title":210,"link":211,"pubDate":212,"description":213,"source":179},"An ovarian cancer study found Ernexa’s cell therapy combo cleared tumors; 100% of animals survived through follow-up. - stocktitan.net","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivAFBVV95cUxPaDU3eHQ0TzVKY0FqOXlTSFNkamVWWGhwbFhadE43QzRBbnpYSF9sOERZVzlsUUN0SnlydGNSQ0lIeUdwQWFGOXhZM1hza09Uc2poenVKWFpnNThPblNoSW94a2lPWllJMkFfY2NlRkdCYkRQU2FRQ2VjLXJZemlwMHZZRVU0eGNoaDlFRkVyQXB4N0o4NGZYVk1iVXVNcmJaOWswLUwtb19qd0ZfWlZnSHQzbWpONFA4VkZrVg?oc=5","Tue, 29 Sep 2026 13:15:00 GMT","An ovarian cancer study found Ernexa’s cell therapy combo cleared tumors; 100% of animals survived through follow-up. stocktitan.net",{"title":215,"link":216,"pubDate":217,"description":218,"source":219},"Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com - Investing.com Nigeria","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxPV0dOR3F4ZGpCeFcxYUxFSWcxZHZPa0FmSE1DUEdqc09FU3ppU0tmY1dfZ3hRSmFmOUNPLVE1OWc1SE4wLVhfZ3liNlZaRUEycFN5WFFsWTA1bVZRX2dmTDhWZXFrQTNSSlpnM19yZDdqMTRMT1ZWaHZNa1NpQkxXNy1DdFRMTjNmN2NYUGtSRHdvUC1rLUFQN2o2OXVkaC1ydk9WUmFsUTVFWGR5X1hGbWxLakZQRERaSmhn?oc=5","Thu, 01 Oct 2026 14:27:20 GMT","Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com Investing.com Nigeria","Investing.com Nigeria",{"title":221,"link":222,"pubDate":223,"description":224,"source":225},"Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxOOEtxX09SNEEydVAxbnZqM3JoN0dkVml5RGlPZlJzM2hZZXJiRm9SZ3dhYWZDbzZCb09CN2Y1TFhfVFpZVzhjOG1pcW14OTdhNElqQkR5NGdiUnZYZ2pPVFNaekpjeDhGeXRHY0FqUHpvc0pxV1RjVkFESHc0MDhfaGJhejZLeHBBNTZsdXhEdlZ6aUZYTGRKU0diX01pLUN4dHZxR0Jfd193UXBUajRBVG1ONXg3UVJPNTdj?oc=5","Wed, 30 Sep 2026 12:38:00 GMT","Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com Investing.com UK","Investing.com UK",{"title":227,"link":228,"pubDate":229,"description":230,"source":225},"Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxOeThXQ251VzdDZG5Vb24taTNWSjNsTVlhelRSckp4dmlsekpucTNoM1U2emdCdE1SbFo5X1BzeGp4OWoxZW1oUlh1LTFwZ05XOE5BY29RWmVnaGpKS3FGT1VUWnYyNmRtTzZJX2p4S2hIREV5aGd2TFZ6Yzg5RVJ5WFhlTFpVSi1vZWg1dTBmMEtLS1p3aDBfQVRnQkZBNnRLTGVjNzNmNGJGdTFEeWJjWHU5dFZMT3VQSTJn?oc=5","Thu, 01 Oct 2026 13:26:00 GMT","Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com Investing.com UK"]